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Background
HCV infection induces hepatic and extra-hepatic damage
that includes kidney and neurocognitive dysfunction.
Tryptophan (Trp) is catabolized into immunosuppressive
kynurenine (Kyn) by indoleamine 2,3-dioxygenase (IDO)
and tryptophan 2,3 dioxegenase (TDO). Increased Trp cat-
abolism measured by Kyn/Trp ratio has been associated
with neurocognitive impairment and immune dysfunction
in HIV mono-infection. Here, we assessed the contribu-
tion of Trp catabolism in HCV/HIV co-infected patients.
Methods
Plasma samples were collected from ART-treated (HIV
RNA <40 copies/ml) HCV/HIV co-infected patients with
or without liver fibrosis (n=20 per group), HBV/HIV
co-infected patients (n=25), ART-treated and untreated
HIV-mono-infected patients and 30 healthy subjects (HS),
(n=30 per group). Furthermore, 17 additional HCV/HIV
INF-a/ribavirin treated patients were longitudinally
assessed before and 6 months after sustained virological
response (SVR). IDO and TDO enzymatic activity
(Kyn/Trp ratio) was measured by isotope dilution tandem
mass spectrometry. Statistical analyses were performed
using Anova, unpaired or paired t-tests and Spearman
correlation tests.
Results
Among HCV/HIV patients, those having fibrosis compared
with non-fibrosis had higher APRI scores (2.48±0.23 vs
0.36±0.018, p<0.0001) and elevated Kyn levels (2.6±0.24 vs.
1.97±0.15 µmol/L, p=0.038). For HBV/HIV co-infected,
Kyn level was also elevated (2.1±0.16 µmol/L). The
Kyn/Trp ratio was equally elevated in all HCV and HBV
co-infected groups, similar to the untreated mono-infected
HIV group. Importantly, HCV/HIV fibrotic and HBV/HIV
groups but not the non-fibrotic group had higher Kyn/Trp
ratios compared to the ART-treated and HS groups. Unlike
HIV viremia, HCV viremia was not correlated with the
Kyn/Trp ratio. However, in all HCV/HIV co-infected
patients, Kyn/Trp ratio was correlated with the APRI score
(p=0.027). Successful HCV treatment improved APRI
score (0.89±0.13 vs. 0.4±0.04, p=0.001), contrasting with
unchanged elevated Kyn/Trp ratios six months after SVR.
Conclusion
ART-treated HCV/HIV and HBV/HIV co-infected patients
presented with elevated immunosuppressive Kyn/Trp ratios
when compared to mono-infected HIV-treated patients
and reached a ratio similar to the untreated HIV mono-
infected patients. In ART-treated patients, liver fibrosis on
its own, but not HCV viremia, was associated with an
enhanced level of immunosuppressive Tryptophan catabo-
lism. These findings suggest that a necrotico-inflammatory
liver syndrome persists even after SVR, and subsequently
induces a systemic immune activation by increasing trypto-
phan catabolism.
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